Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gianni, L.
Right arrow Articles by Martini, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gianni, L.
Right arrow Articles by Martini, C.

Journal of Clinical Oncology, Vol 13, 2688-2699, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study

L Gianni, E Munzone, G Capri, F Fulfaro, E Tarenzi, F Villani, C Spreafico, A Laffranchi, A Caraceni and C Martini
Division of Medical Oncology, Istituto Nazionale Tumori, Milano, Italy.

PURPOSE: To define the maximum-tolerated dose (MTD) and better tolerated sequence of paclitaxel by 3-hour infusion plus bolus doxorubicin (DOX) and to evaluate antitumor efficacy. PATIENTS AND METHODS: Thirty-five women with metastatic breast cancer (dominant visceral metastases in 56%, and involvement of > or = three sites in 67%) who never received chemotherapy of any type were studied. Paclitaxel every 3 weeks (125 mg/m2 starting dose) was increased by 25- mg/m2 steps in subsequent cohorts of patients. DOX (60 mg/m2 fixed dose) was administered 15 minutes before the start of or after the end of paclitaxel for a maximum of eight cycles. Subsequently, patients in continuous response could receive single-agent paclitaxel (175 to 200 mg/m2 every 3 weeks). The drug sequence was alternated in consecutive patients and in the first two cycles. RESULTS: Severe neutropenia that lasted greater than 7 days (n = 4), febrile neutropenia (n = 7) and grade III oral mucositis (n = 6) defined the MTD of paclitaxel at 200 mg/m2 in 34 assessable patients. Grade II peripheral neuropathy occurred in 33% of patients. Six women (18%) developed clinically reversible congestive heart failure (CHF) after a median of 480 mg/m2 total DOX. Drug sequence had no effect on toxicities. High efficacy on all metastatic sites in 32 assessable patients accounted for a 41% complete response (CR) rate (95% confidence interval [CI], 24% to 59%) and 94% overall-response rate (95% CI, 79% to 99%). After a median follow-up of 12 months (range 3 to 18), the median response duration is 8 months (range, 2+ to 18+) for complete responders and 11 months (range 1+ to 15+) for partial responders. CONCLUSION: The rate of CR and incidence of CHF may be an expression of therapeutic and toxic enhancement due to the schedule used in this trial. Until clarification of this possibility, this promising combination should be used in investigational trials.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu
Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling
Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Salvatorelli, P. Menna, L. Gianni, and G. Minotti
Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 790 - 800.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Roche, P. Fumoleau, M. Spielmann, J.-L. Canon, T. Delozier, D. Serin, M. Symann, P. Kerbrat, P. Soulie, F. Eichler, et al.
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
J. Clin. Oncol., December 20, 2006; 24(36): 5664 - 5671.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Gennari, D. Amadori, M. De Lena, O. Nanni, P. Bruzzi, V. Lorusso, L. Manzione, and P. F. Conte
Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer
J. Clin. Oncol., August 20, 2006; 24(24): 3912 - 3918.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Salvatorelli, P. Menna, S. Cascegna, G. Liberi, A. M. Calafiore, L. Gianni, and G. Minotti
Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 424 - 433.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. Couture, J. A. Nash, and J. Turgeon
The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart.
Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Marty, M. Espie, A. Llombart, A. Monnier, B. L. Rapoport, V. Stahalova, and On behalf of the Dexrazoxane Study Group
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
Ann. Onc., April 1, 2006; 17(4): 614 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Fumoleau, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al.
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group Results
Ann. Onc., January 1, 2006; 17(1): 85 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Llombart Cussac, et al.
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Clin. Cancer Res., December 15, 2005; 11(24): 8715 - 8721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. E. Langley, J. Carmichael, A. L. Jones, D. A. Cameron, W. Qian, B. Uscinska, A. Howell, and M. Parmar
Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01
J. Clin. Oncol., November 20, 2005; 23(33): 8322 - 8330.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Floyd, D. T. Nguyen, R. L. Lobins, Q. Bashir, D. C. Doll, and M. C. Perry
Cardiotoxicity of Cancer Therapy
J. Clin. Oncol., October 20, 2005; 23(30): 7685 - 7696.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Martin, T. Pienkowski, J. Mackey, M. Pawlicki, J.-P. Guastalla, C. Weaver, E. Tomiak, T. Al-Tweigeri, L. Chap, E. Juhos, et al.
Adjuvant Docetaxel for Node-Positive Breast Cancer
N. Engl. J. Med., June 2, 2005; 352(22): 2302 - 2313.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic, M. Welnicka-Jaskiewicz, C. Wiltschke, Z. Kahan, M. Grgic, V. Tzekova, M. Inbar, J. Cervek, et al.
Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial
J. Clin. Oncol., March 1, 2005; 23(7): 1401 - 1408.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Dieras, P. Fumoleau, G. Romieu, M. Tubiana-Hulin, M. Namer, L. Mauriac, J.-P. Guastalla, E. Pujade-Lauraine, P. Kerbrat, P. Maillart, et al.
Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide As Neoadjuvant Treatment of Patients With Breast Cancer
J. Clin. Oncol., December 15, 2004; 22(24): 4958 - 4965.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Fountzilas, H. P. Kalofonos, U. Dafni, C. Papadimitriou, D. Bafaloukos, P. Papakostas, A. Kalogera-Fountzila, H. Gogas, G. Aravantinos, L. A. Moulopoulos, et al.
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
Ann. Onc., October 1, 2004; 15(10): 1517 - 1526.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Briasoulis, G. Pentheroudakis, V. Karavasilis, E. Tzamakou, D. Rammou, and N. Pavlidis
Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors
Ann. Onc., October 1, 2004; 15(10): 1566 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. F. Fleming, V. L. Filiaci, R. C. Bentley, T. Herzog, J. Sorosky, L. Vaccarello, and H. Gallion
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study
Ann. Onc., August 1, 2004; 15(8): 1173 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bottomley, L. Biganzoli, T. Cufer, R. E. Coleman, C. Coens, F. Efficace, H. A. Calvert, T. Gamucci, C. Twelves, P. Fargeot, et al.
Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study
J. Clin. Oncol., July 1, 2004; 22(13): 2576 - 2586.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Gligorov and J. P. Lotz
Preclinical Pharmacology of the Taxanes: Implications of the Differences
Oncologist, June 2, 2004; 9(suppl_2): 3 - 8.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Crown, M. O'Leary, and W.-S. Ooi
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
Oncologist, June 2, 2004; 9(suppl_2): 24 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Cresta, G. Grasselli, M. Mansutti, A. Martoni, G. Lelli, G. Capri, F. Buzzi, G. Robustelli Della Cuna, A. Jirillo, E. Terzoli, et al.
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer
Ann. Onc., March 1, 2004; 15(3): 433 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. To, M. Shin, M. Tabuchi, H. Sakaguchi, A. Takeuchi, N. Matsunaga, S. Higuchi, and S. Ohdo
Influence of Dosing Schedule on Toxicity and Antitumor Effects of a Combination of Adriamycin and Docetaxel in Mice
Clin. Cancer Res., January 15, 2004; 10(2): 762 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Bianchi, J. Albanell, W. Eiermann, G. Vitali, D. Borquez, L. Vigano, R. Molina, G. Raab, A. Locatelli, B. Vanhauwere, et al.
Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5944 - 5951.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
E. P. Mamounas
NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions
Clin. Med. Res., October 1, 2003; 1(4): 309 - 326.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Lunardi, M. O. Vannozzi, C. Bighin, L. Del Mastro, I. Stevani, G. Schettini, and M. Venturini
Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients
Ann. Onc., August 1, 2003; 14(8): 1222 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Pectasides, M. Pectasides, D. Farmakis, N. Bountouroglou, M. Nikolaou, M. Koumpou, N. Mylonakis, and C. Kosmas
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study
Ann. Onc., April 1, 2003; 14(4): 537 - 542.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Valero and G. N. Hortobagyi
Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?
J. Clin. Oncol., March 15, 2003; 21(6): 959 - 962.
[Full Text] [PDF]

Home page
 JCOHome page
A. D. Seidman
Sequential Single-Agent Chemotherapy for Metastatic Breast Cancer: Therapeutic Nihilism or Realism?
J. Clin. Oncol., February 15, 2003; 21(4): 577 - 579.
[Full Text] [PDF]

Home page
 The OncologistHome page
D. Miles, G. von Minckwitz, and A. D. Seidman
Combination Versus Sequential Single-Agent Therapy in Metastatic Breast Cancer
Oncologist, December 1, 2002; 7(90006): 13 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Gogas, C. Papadimitriou, H. P. Kalofonos, D. Bafaloukos, G. Fountzilas, D. Tsavdaridis, A. Anagnostopoulos, A. Onyenadum, P. Papakostas, T. Economopoulos, et al.
Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx(R)) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group
Ann. Onc., November 1, 2002; 13(11): 1737 - 1742.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Rischin, S. P. Ackland, J. Smith, M. B. Garg, S. Clarke, M. J. Millward, G. C. Toner, and J. Zalcberg
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics
Ann. Onc., November 1, 2002; 13(11): 1810 - 1818.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. H. Giordano, D. J. Booser, J. L. Murray, N. K. Ibrahim, Z. U. Rahman, V. Valero, R. L. Theriault, M. F. Rosales, E. Rivera, D. Frye, et al.
A Detailed Evaluation of Cardiac Toxicity: A Phase II Study of Doxorubicin and One- or Three-Hour-Infusion Paclitaxel in Patients with Metastatic Breast Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3360 - 3368.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Biganzoli, T. Cufer, P. Bruning, R. Coleman, L. Duchateau, A.H. Calvert, T. Gamucci, C. Twelves, P. Fargeot, R. Epelbaum, et al.
Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
J. Clin. Oncol., July 15, 2002; 20(14): 3114 - 3121.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Vici, G. Colucci, V. Gebbia, A. Amodio, F. Giotta, F. Belli, F. Conti, N. Gebbia, G. Pezzella, M. R. Valerio, et al.
First-Line Treatment With Epirubicin and Vinorelbine in Metastatic Breast Cancer
J. Clin. Oncol., June 1, 2002; 20(11): 2689 - 2694.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Speyer
Cardiac Dysfunction in the Trastuzumab Clinical Experience
J. Clin. Oncol., March 1, 2002; 20(5): 1156 - 1157.
[Full Text] [PDF]

Home page
 The OncologistHome page
D. L. Keefe
The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern?
Oncologist, February 1, 2002; 7(1): 65 - 72.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Hainsworth, H. A. Burris III, D. A. Yardley, J. E. Bradof, M. Grimaldi, L. A. Kalman, T. Sullivan, M. Baker, J. B. Erland, and F. A. Greco
Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial
J. Clin. Oncol., August 1, 2001; 19(15): 3500 - 3505.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. S. Aapro
Adjuvant Therapy of Primary Breast Cancer: A Review of Key Findings from the 7th International Conference, St. Gallen, February 2001
Oncologist, August 1, 2001; 6(4): 376 - 385.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Khayat, P. Chollet, E. C. Antoine, S. Monfardini, G. Ambrosini, A. Benhammouda, M.-F. Mazen, R. Sorio, O. Borg-Olivier, A. Riva, et al.
Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer
J. Clin. Oncol., July 15, 2001; 19(14): 3367 - 3375.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. L. Shapiro and A. Recht
Side Effects of Adjuvant Treatment of Breast Cancer
N. Engl. J. Med., June 28, 2001; 344(26): 1997 - 2008.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Minotti, A. Saponiero, S. Licata, P. Menna, A. M. Calafiore, G. Teodori, and L. Gianni
Paclitaxel and Docetaxel Enhance the Metabolism of Doxorubicin to Toxic Species in Human Myocardium
Clin. Cancer Res., June 1, 2001; 7(6): 1511 - 1515.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Crown
Docetaxel: Overview of an Active Drug for Breast Cancer
Oncologist, June 1, 2001; 6(2008): 1 - 4.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.-M. Nabholtz and A. Riva
Taxane/Anthracycline Combinations: Setting a New Standard in Breast Cancer?
Oncologist, June 1, 2001; 6(2008): 5 - 12.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Sessa and O. Pagani
Docetaxel and Epirubicin in Advanced Breast Cancer
Oncologist, June 1, 2001; 6(2008): 13 - 16.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Grasselli, L. Vigano, G. Capri, A. Locatelli, E. Tarenzi, C. Spreafico, A. Bertuzzi, A. Giani, C. Materazzo, S. Cresta, et al.
Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer
J. Clin. Oncol., April 15, 2001; 19(8): 2222 - 2231.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Fountzilas, C. Papadimitriou, U. Dafni, D. Bafaloukos, D. Skarlos, L. A. Moulopoulos, E. Razis, H. P. Kalofonos, G. Aravantinos, E. Briassoulis, et al.
Dose-Dense Sequential Chemotherapy With Epirubicin and Paclitaxel Versus the Combination, as First-Line Chemotherapy, in Advanced Breast Cancer: A Randomized Study Conducted by the Hellenic Cooperative Oncology Group
J. Clin. Oncol., April 15, 2001; 19(8): 2232 - 2239.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi
Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Oncologist, April 1, 2001; 6(2): 133 - 146.
[Abstract] [Full Text]

Home page
 JCOHome page
J. Jassem, T. Pienkowski, A. Pluzanska, S. Jelic, V. Gorbunova, Z. Mrsic-Krmpotic, J. Berzins, T. Nagykalnai, N. Wigler, J. Renard, et al.
Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial
J. Clin. Oncol., March 15, 2001; 19(6): 1707 - 1715.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Taamma, J. L. Misset, M. Riofrio, C. Guzman, E. Brain, L. Lopez Lazaro, H. Rosing, J. M. Jimeno, and E. Cvitkovic
Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors
J. Clin. Oncol., March 1, 2001; 19(5): 1256 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. F. Fleming, J. M. Fowler, S. E. Waggoner, L. J. Copeland, B. E. Greer, I. Horowitz, G. Sutton, R. J. Schilder, P. M. Fracasso, H. G. Ball, et al.
Phase I Trial of Escalating Doses of Paclitaxel Combined With Fixed Doses of Cisplatin and Doxorubicin in Advanced Endometrial Cancer and Other Gynecologic Malignancies: A Gynecologic Oncology Group Study
J. Clin. Oncol., February 15, 2001; 19(4): 1021 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Nabholtz, J. R. Mackey, M. Smylie, A. Paterson, D. R. Noel, T. Al-Tweigeri, K. Tonkin, S. North, N. Azli, and A. Riva
Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer
J. Clin. Oncol., January 15, 2001; 19(2): 314 - 321.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al.
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. D. Britten, S. D. Baker, L. J. Denis, T. Johnson, R. Drengler, L. L. Siu, K. Duchin, J. Kuhn, and E. K. Rowinsky
Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel
Clin. Cancer Res., September 1, 2000; 6(9): 3459 - 3468.
[Abstract] [Full Text]

Home page
 J Oncol Pharm PractHome page
J. Crown and W. Palmby
Docetaxel: use in non--small cell lung cancer and metastatic breast cancer and formulation update
Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S11 - S21.
[Abstract] [PDF]